Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
Source: View publication →
In patients with myocardial injury after non-cardiac surgery (MINS), treatment with dabigatran 110 mg twice daily significantly reduced the risk of major vascular complications without a significant increase in major bleeding compared with placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MANAGE trial provides the first randomized evidence suggesting that postoperative anticoagulation with dabigatran may mitigate the high cardiovascular risk associated with MINS, an often-overlooked entity that independently predicts short- and long-term mortality.
Historical Context
MINS was historically under-recognized due to its frequent lack of ischemic symptoms. Previous research identified MINS as a major independent predictor of 30-day and 1-year mortality, yet clinical practice lacked established, evidence-based management strategies until this trial evaluated the role of targeted anticoagulation.
Guided Discussion
High-yield insights from every perspective
What is the primary pathophysiology of Myocardial Injury after Non-cardiac Surgery (MINS), and how does the mechanism of dabigatran address the subsequent risk of vascular events?
Key Response
MINS is often asymptomatic and detected only by troponin elevation; it involves both Type 1 MI (plaque rupture) and Type 2 MI (supply-demand mismatch). Dabigatran is a direct thrombin inhibitor that prevents the conversion of fibrinogen to fibrin and inhibits thrombin-induced platelet aggregation, thereby reducing the formation of thrombi in the high-stress, prothrombotic state that follows major surgery.
In a patient diagnosed with MINS who is already on Aspirin for secondary prevention, how should the findings of the MANAGE trial influence your decision to add dabigatran 110 mg twice daily, and what clinical monitoring is essential?
Key Response
The MANAGE trial demonstrated that dabigatran reduced a composite of major vascular complications (HR 0.72). However, clinicians must balance this against the high rate of drug discontinuation seen in the trial (46%). Monitoring renal function (CrCl) is essential as dabigatran is 80% renally cleared, and the risk of bleeding—while not statistically significantly increased for 'major' bleeds in the trial—is higher when combined with antiplatelet therapy.
The MANAGE trial's primary composite endpoint included 'vascular death, MI, stroke, peripheral arterial embolism, amputation, and symptomatic VTE.' Which specific component showed the most robust benefit, and how does this affect the interpretation of dabigatran's role in 'cardiac' vs 'vascular' protection post-MINS?
Key Response
The reduction in stroke (HR 0.20) was one of the most striking findings in MANAGE, whereas the reduction in MI alone was not statistically significant. This suggests that dabigatran's primary benefit in MINS may be more related to preventing embolic or thrombotic stroke in a vulnerable population rather than solely preventing recurrent myocardial events, highlighting the broad 'vascular' risk associated with MINS.
Given the high rate of study drug discontinuation (46%) in the MANAGE trial, how does this 'intention-to-treat' reality affect your confidence in prescribing dabigatran for MINS in a real-world surgical population with polypharmacy and potential post-operative complications?
Key Response
High discontinuation rates often suggest poor tolerability or logistical hurdles (e.g., dyspepsia, bleeding concerns, or surgical re-interventions). While the ITT analysis remained significant, the real-world benefit may be lower if patients cannot remain on therapy for the intended duration. It teaches that while the evidence supports the drug, patient selection and adherence strategies are as critical as the prescription itself.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MANAGE trial was terminated early due to slow recruitment and underwent a mid-trial modification of the primary composite endpoint. How do these factors potentially inflate the treatment effect, and what statistical adjustments are necessary to mitigate the 'winner's curse' in this context?
Key Response
Early termination for futility or slow recruitment, combined with endpoint modification (adding VTE and amputation), can lead to an overestimation of treatment effects (Type I error inflation). A PhD-level critique would look for sensitivity analyses using the original endpoint and evaluate the alpha-spending functions used to ensure that the reported p-values remain robust despite the trial's evolution.
The MANAGE trial utilized a definition of 'major bleeding' that may differ from the ISTH or TIMI criteria used in other NOAC trials. As a reviewer, how would you challenge the authors on the safety profile, specifically regarding the 'clinically important' but non-major bleeding events?
Key Response
Reviewers would note that while 'major bleeding' (life-threatening or critical organ) was not significantly higher, 'clinically important' bleeding was higher in the dabigatran group. Editors look for whether the 'net clinical benefit' accounts for minor bleeds that, in a post-surgical patient, can lead to wound complications, hematomas, and prolonged hospital stays, which are often not captured in a traditional 'major bleeding' metric.
The 2020 ESC and 2017 CCS guidelines emphasize the detection of MINS via troponin screening. Should MANAGE support a Class I recommendation for dabigatran in all MINS patients, or should it remain a lower-tier recommendation based on the evidence's limitations?
Key Response
Current guidelines generally give dabigatran a Class IIb recommendation for MINS because it is supported by only one large trial with significant discontinuation rates. Unlike the POISE-1 (Aspirin) or the use of statins, the evidence for dabigatran is promising but lacks the reproducibility across multiple large-scale RCTs required for a Class I 'must-do' recommendation in the perioperative standard of care.
Clinical Landscape
Noteworthy Related Trials
POISE Trial
Tested
Metoprolol succinate extended-release
Population
Patients undergoing non-cardiac surgery
Comparator
Placebo
Endpoint
Composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal cardiac arrest
RE-LY Trial
Tested
Dabigatran etexilate 110 mg or 150 mg
Population
Patients with atrial fibrillation
Comparator
Warfarin
Endpoint
Composite of stroke or systemic embolism
POISE-2 Trial
Tested
Clonidine or Aspirin
Population
Patients undergoing non-cardiac surgery at risk for cardiovascular complications
Comparator
Placebo
Endpoint
Composite of death and nonfatal myocardial infarction
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis